STX-1400 A preclinical X-Editor gene-editing therapy targeting APOC3 to durably lower triglyceride-rich lipoproteins and reduce pancreatitis and cardiovascular risk.
Visit productCosigns Received
Be the first Cosign
Put your name behind STX-1400.
Add it to your Products I use list and share why you use it.